CoChat

Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials

Karagiannis, T., Liakos, A., Bekiari, E., Athanasiadou, E., Paschos, P., Vasilakou, D., Mainou, M., Rika, M., Boura, P., Matthews, D. R., Tsapas, A. · 2015 · Diabetes, Obesity and Metabolism
Cited by 56

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aim: To assess the efficacy and safety of recently approved once‐weekly glucagon‐like peptide 1 receptor agonists ( GLP ‐1 RAs ) in patients with type 2 diabetes. Methods: We conducted a systematic review and meta‐analysis of randomized controlled trials comparing any GLP ‐1 RA licensed for once‐weekly dosing (albiglutide, dulaglutide or exenatide extended release) with placebo or other antidiabetic agents. We searched M edline, E mbase, the C ochrane L ibrary and grey literature for articles published up to D ecember 2014 and extracted data in duplicate. Results: In our systematic review we included 33 trials with a total of 16 003 participants. Compared with placebo the change in glycated haemoglobin ( HbA1c ) concentration was −0.66% [six studies; 95% confidence interval ( CI ) −1.14 to −0.19; I 2 = 88%] with albiglutide, and −1.18% (seven studies; 95% CI −1.34 to −1.02; I 2 = 65%) with dulaglutide. Based on data from placebo‐controlled trials, we did not detect statistically significant weight‐sparing benefits for albiglutide or dulaglutide. Compared with other antidiabetic agents, once‐weekly GLP ‐1 RAs outperformed sitagliptin, daily exenatide and insulin glargine in terms of HbA1c ‐lowering (mean differences −0.40%; 95% CI −0.66 to −0.14; I 2 = 85%, −0.44%; 95% CI −0.58 to −0.29; I 2 = 40% and −0.28; 95% CI −0.45 to −0.10; I 2 = 81%, respectively). The main adverse effects of treatment included gastrointestinal and injection site reactions. Conclusions: Given their dosing scheme and overall efficacy and safety profile, once‐weekly GLP ‐1 RAs are a convenient therapeutic option for use as add‐on to metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12541

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 56

Metadata

Authors
Karagiannis, T., Liakos, A., Bekiari, E., Athanasiadou, E., Paschos, P., Vasilakou, D., Mainou, M., Rika, M., Boura, P., Matthews, D. R., & Tsapas, A.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-09-23
Volume
17
Issue
11
Pages
1065-1074
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1950437517
Cited by
56
References
14
FWCI
2.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1111/dom.12541
The paper
Karagiannis, T., Liakos, A., Bekiari, E., Athanasiadou, E., Paschos, P., Vasilakou, D., Mainou, M., Rika, M., Boura, P., Matthews, D. R., & Tsapas, A. (2015). Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12541

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.